Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.

28 Yet, when study subjects were selected for high disease activity (HDA) defined as two or more relapses in the year prior to study, with or without high T2 burden of disease or T1 Gd+ lesions, or EDSS score 3.5 or greater, there were highly significant reductions in ARR and MRI lesion activity, and prolonged time to sustained disability at both cumulative doses 45 (see Table 3 ).

also in 132,142 other papers